TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03284307
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 participants will be administered Midazolam.
Study: NCT00578734
Drug: Lucinactant
Normalized name: Lucinactant
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow intra-tracheal instillation
Study: NCT01404936
Drug: Interferon-2A
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 (x106 IU/m\^2) subcutaneously on days 1-4.
Study: NCT01404936
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 by vein on day 4.
Study: NCT01404936
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m\^2 by vein on day 4.
Study: NCT01404936
Drug: Velban
Normalized name: Velban
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m\^2 by vein on day 4.
Study: NCT01404936
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg/m\^2 by vein on day 4.
Study: NCT00633217
Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment drug
Study: NCT00407056
Drug: Difluprednate Ophthalmic Emulsion
Normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00633217
Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment drug
Study: NCT00657176
Drug: OPB-31121
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 100mg tablet~* oral administration, Qd
Study: NCT00777920
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet administered orally once daily
Study: NCT00186082
Drug: Cefotetan or Cefoxitin vs placebo
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm.
Study: NCT04688008
Drug: Hetrombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions
Study: NCT01424215
Drug: Indocyanine Green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
Study: NCT00649714
Drug: Zonisamide Capsules 100 mg
Normalized name: zonisamide Oral Capsule
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg, single dose fed
Study: NCT01417377
Drug: Mircera
Normalized name: Mircera
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
Study: NCT02873702
Drug: Dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules.
Study: NCT02873702
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole capsules.
Study: NCT02461407
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib p.o. qd
Study: NCT04110288
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel to treat peripheral arterial disease
Study: NCT04831255
Drug: triamcinolone acetonide extended-release injectable suspension
Normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
Study: NCT01977482
Drug: rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO will be procured from local market
Study: NCT00221416
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-20 mg/day
Study: NCT02405377
Drug: Visipaque
Normalized name: Visipaque
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study: NCT02405377
Drug: 0.9% sodium chloride ﬂuid administration
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00392067
Drug: Calcipotriol and LEO80122 (LEO19123 cream)
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00795886
Drug: RAPAMYCIN
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
Study: NCT00131937
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03931369
Drug: Tolvaptan 15 MG
Normalized name: tolvaptan 15 MG
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single administration of one pill of 15 MG tolvaptan
Study: NCT00433043
Drug: Beta blocker (carvedilol or metoprolol succinate)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
Study: NCT00786370
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Study: NCT00786370
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
Study: NCT00786370
Drug: Dexemedetomidine
DrugBank: Medetomidine (DB11428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Study: NCT00000369
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04922541
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
Study: NCT04213248
Drug: Umbilical Mesenchymal Stem Cells derived Exosomes
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
Study: NCT01650597
Drug: JNJ-42165279 2.5 - 500 mg oral
DrugBank: JNJ-42165279 (DB15173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
Study: NCT01650597
Drug: JNJ-42165279 100 mg oral
Normalized name: JNJ-42165279
DrugBank: JNJ-42165279 (DB15173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
Study: NCT01931319
Drug: Intravenous baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02141828
Drug: EPZ-5676
Normalized name: Epzicom
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
Study: NCT00563472
Drug: estetrol
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg orally per day for 28 days
Study: NCT00563472
Drug: estetrol
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg orally per day for 28 days
Study: NCT00563472
Drug: estetrol and desogestrel
Normalized name: drospirenone and estetrol
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg estetrol and 150 microg desogestrel orally per day for 28 days
Study: NCT00563472
Drug: estetrol and progesterone
Normalized name: drospirenone and estetrol
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg estetrol and 200 mg progesterone orally per day for 28 days
Study: NCT03252925
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/Kg.d, oral
Study: NCT04047797
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth
Study: NCT04047797
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth
Study: NCT04396236
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT00458978
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01635426
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 75 mg daily for 2 months after meals
Study: NCT01635426
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg daily for 2 months after meals
Study: NCT00357552
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily
Study: NCT00357552
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twice daily
Study: NCT04320589
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
Study: NCT02495519
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400 mg/day until disease progression
Study: NCT00839319
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ug/kg subcutaneous injections on Day 1.
Study: NCT00839319
Drug: hCG (human chorionic gonadotropin)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 IU subcutaneous injection every other day for 10 days (5 doses)
Study: NCT00839319
Drug: hCG (human chorionic gonadotropin)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 IU subcutaneous injection
Study: NCT00839319
Drug: hCG (human chorionic gonadotropin)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 IU subcutaneous injection
Study: NCT00818701
Drug: low dose Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide infusion 0.005ug/kg/min
Study: NCT00818701
Drug: nesiritide, Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide 0.005ug/kg/min Sildenafil 50 mg
Study: NCT04323657
Drug: TC-110 T Cells
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-110 T Cells
Study: NCT04323657
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu/Cy Lymphodepletion
Study: NCT02301416
Drug: Phentermine/topiramate
Normalized name: PHENTERMINE/TOPIRAMATE
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
Study: NCT03419559
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-L1 antagonist monoclonal antibody
Study: NCT02892916
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
Study: NCT01847326
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01847326
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01847326
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00387790
Drug: motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01873534
Drug: FMX-8
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
Study: NCT03658590
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
Study: NCT03658590
Drug: Distilled Water
Normalized name: Distilled Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a prefilled syringe with two milliliters of distilled water intravenously.
Study: NCT02404025
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
Study: NCT02404025
Drug: Rabbit ATG
Normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
Study: NCT02404025
Drug: CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
Study: NCT03134703
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
Study: NCT03134703
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
Study: NCT03257319
Drug: inhaled titration of morphine chlorhydrate
Normalized name: Ocean brand of sodium chloride Inhalant Product
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient in arm A will receive 1 to 3 titration
Study: NCT03257319
Drug: IV titration of morphine chlorhydrate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient in arm BA will receive 1 to 6 injection
Study: NCT00254384
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00254384
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00254384
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00254384
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03925779
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine sedation
Study: NCT03925779
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol sedation
Study: NCT00862667
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 300ug using Inhaler C
Study: NCT00076544
Drug: Ziconotide
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02119858
Drug: indocyanine green solution
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given transperineally
Study: NCT00673738
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.
Study: NCT00140582
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Study: NCT04504552
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
Study: NCT03053102
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan was administered as multiple oral doses over a period of at least 28 days.
Study: NCT01499277
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ceftaroline 600mg every 8 hours
Study: NCT01499277
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV vancomycin 15mg/kg every 12 hours
Study: NCT01499277
Drug: Aztreonam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV aztreonam 1 g every 8 hours
Study: NCT04518800
Drug: Jin Youli(PEG-rhG-CSF)
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
Study: NCT01423747
Drug: VP16
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
Study: NCT01423747
Drug: Fludarabine, OKT3, Treosulfan, Thiotepa
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
Study: NCT00476853
Drug: HAART containing nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.